From July 22 to 24, 2026,TONACEA will host The 1st China Pharmaceutical Innovation Conference(CPIC 2026)at the National Exhibition and Convention Center (Shanghai).

CPIC 2026 will establish a model of “China Innovation – Global Partnerships – Shanghai Dealmaking”. As the premier gateway for international capital to navigate China’s innovation ecosystem, and a strategic hub for Chinese pharmaceutical companies to scale globally, CPIC will undoubtedly set the benchmark for investment and partnership in the healthcare industry. CPIC will feature over 60 specialized sessions covering hot topics and future directions in healthcare innovation investment and globalization.

Going global has become an inevitable choice for Chinese pharmaceutical enterprises. Yet, the journey is never smooth. What hidden pitfalls tend to be overlooked in BD transactions? How can legal hurdles amid supply chain globalization be resolved? When choosing a listing destination, which market offers the optimal solution: the STAR Market, the Hong Kong Stock Exchange, or the US stock market?

Today, the agenda of the New Models for Cross-border Pharmaceutical Cooperation Session, co-hosted by JunHe LLP and Tonacea, is officially released. The session gathers senior legal experts from JunHe specializing in hot-button issues within the pharmaceutical industry. Centering on practical lessons of overseas BD expansion, supply chain legal risks, and listing strategy selection, the session will thoroughly analyze key links and breakthrough approaches for pharmaceutical globalization.
We look forward to exploring innovative models and paths for cross-border pharmaceutical cooperation with you at the National Exhibition and Convention Center (Shanghai) from July 22 to 24.

Special Session Agenda

Co-hosted: JunHe Law Firm

Topic 1: Hurdles and Pitfalls in Overseas BD Transactions
Gerry Zhao：Partner, JunHe LLP

Gerry is a partner at JunHe LLP. He has a dual background in medicine  and law, and prior to joining JunHe, he worked at Hengrui Pharmaceuticals, where he gained experience in early-stage pharmaceutical research and development.
Gerry has not only managed a substantial number of patent matters and intellectual property due diligence projects but has also led over 200 BD transactions in the pharmaceutical field, including SiranBio with GSK, Antengene with UCB, Degrontx and Usynova with MSD, Simcere Zaiming with Ipsen and NextCure, Genor Biopharma with TRC 2004, ImmuneOnco with Instil Bio, MediLink with BioNTech, Biocytogen with Ideaya, Gilead, Neurocrine, and ABL, Elpiscience with Astellas, Usynova with AstraZeneca, Jacobio Pharma with Allist, as well as Imunopharm with Huadong Medicine.

Topic 2: Legal Pain Points and Challenges of the Global Pharmaceutical Supply Chain
Frank Zhou：Partner, JunHe LLP
Frank is a senior partner in JunHe’s corporate and M&A practice group. He also co-chairs JunHe’s life sciences and healthcare practice group. 
Frank has played key roles in many M&A, financing and joint venture deals. He not only advises multinational companies, state-owned companies, public companies and equity funds, but also helps the financing and business development of many small and medium sized companies. He has solid experience in life science, healthcare, manufacturing, FMCG, high-tech and Internet sectors. 
In the life science and healthcare industry, Frank renders a wide variety of legal services needed in the industry, encompassing full enterprise lifecycle and full product lifecycle: (i) private equity, M&A, joint venture and capital market transactions, (ii) regulatory and compliance advices and defenses in relation to licenses and permits, manufacturing compliance, market access, anti-corruption, anti-monopoly, human genetic resources, advertising, data protection, pharmacovigilance, sanctions, export control and customs law, and (iii) the structuring, drafting, revision and negotiation of license-in/out, co-development, contract manufacturing/services, commercialization and other business development deals. As a veteran lawyer for 20+ years, Frank has represented numerous drug and device companies, food manufacturers, testing and diagnosis service providers, medical aesthetics, cosmetics and other health products providers, bio-techs, bio-pharmas, CXOs, upstream and downstream goods and services suppliers, as well as strategic and financial investors, and has become a preferred choice among clients for his reliable quality and service.
Legal 500 names Frank “Lawyer of the Year: Life Sciences and Healthcare (PRC Firms)” in 2025. Client’s feedback on Frank is as follows: responsive to clients' urgent needs with a strong sense of responsibility, solid legal and industrial expertise, forthright speaking style with focus on core issues, attention to detail, and commitment to delivering pragmatic win-win solutions.

Topic 3: Where to List? Listing Strategy for Biotech & Pharma: STAR Market, HKEX, or US Stock Market?
Bella Chen：Partner, JunHe LLP
Ms. Chen is a partner at JunHe and her practice focuses on capital markets, PE/VC investment, fund formation, debt, restructuring and IPOs. She advises public and private companies on a wide range of matters, including mergers and acquisitions, outbound investment, foreign direct investment, corporate governance and compliance. Ms. Chen has clients in various industrial sectors including medicine, biology, finance, solar energy, telecommunications, media, entertainment, infrastructure.
Ms. Chen has extensive experience in private equity and venture capital investment. Her PE/VC clients include Goldman Sachs, Warburg Pincus, Temasek, Sequoia, Advent, MBK, CDH, CITIC Capital, China Everbright Healthcare, FountainVest, Qiming Venture, Highlight Capital, Prax, CIC, CoBuilder, Yuansheng BioVenture, Stone VC and Biotrack Capital.
Ms. Chen has recently completed over 200 private equity investment and exit projects. M Some of her recent representative transactions include Goldman Sach in its investment I n a medical imaging center and Sequoia Capital in its investment in JD Finance.  Other transactions include CITIC Capital in its investment in Pharmaron, CCBI in its investment in CooTek, Sequoia Capital in its investment in BGI (300676) and China Everbright Healthcare in its investment in Betta Pharma (300588). She also represented CIC in its investment in Didi, Sequoia Capital in its investment in a chain of eye hospitals and a beverage manufacturing company. Ms. Chen also represented Highlight Capital in its investment in Quyi, and an orthopedic medical equipment manufacturing company, and CDH and co-investors in their investment in a NEEQ medical equipment company.  She also currently represents a wide range of companies in PE/VC fund investments, including Face++, Youxin.com, Tuhu.com, Mia, ITjuzi, wajiu.com and Wingtek.